By Gologan, Adrian Acquafondata, Marie; Dhir, Rajiv; Sepulveda, Antonia R Context.-Polymeric immunoglobulin receptor (PIgR) expression has been found in gastric mucosa and gastric cancers, but it is not known whether PIgR expression is related to background intestinal metaplasia nor the patterns of PIgR expression in tumors arising in the distal esophagus and gastroesophageal (GE) junction.

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that an abstract detailing results from the RAV12 Phase 1/2a trial has been accepted as a poster discussion presentation at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Raven biotechnologies has completed enrollment of patients in the maximum tolerated dose cohort expansion segment of its Phase I/IIa trial of RAV12 for the treatment of adenocarcinomas. All patients in the trial have undergone radiographic re-evaluation to assess their response to treatment.

SOUTH SAN FRANCISCO, Calif., Nov. 27 /PRNewswire/

SOUTH SAN FRANCISCO, Calif., Nov. 19 /PRNewswire/